Naringenin restores osteogenic differentiation in TNF-α-Treated bone marrow mesenchymal stem cells by targeting AKR1B1
8.3
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-01 03:49
摘要：
Naringenin, a flavonoid derived from citrus fruits, has been shown to restore osteogenic differentiation in TNF-α-treated human bone marrow mesenchymal stem cells (hBMSCs) by targeting AKR1B1. This study highlights naringenin's potential as a therapeutic agent for inflammatory bone disorders, demonstrating its ability to counteract TNF-α-induced suppression through antioxidant and anti-inflammatory mechanisms. The findings suggest that naringenin could be a promising candidate for addressing dual challenges of inflammation and impaired osteogenesis in conditions like osteoporosis and rheumatoid arthritis.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
Naringenin effectively reversed TNF-α-induced inhibition of osteogenic differentiation.
Study identifies AKR1B1 as a critical mediator in the mechanism of naringenin's action.
Naringenin's antioxidant and anti-inflammatory properties support its therapeutic potential.
真实性检查
否
AI评分总结
Naringenin, a flavonoid derived from citrus fruits, has been shown to restore osteogenic differentiation in TNF-α-treated human bone marrow mesenchymal stem cells (hBMSCs) by targeting AKR1B1. This study highlights naringenin's potential as a therapeutic agent for inflammatory bone disorders, demonstrating its ability to counteract TNF-α-induced suppression through antioxidant and anti-inflammatory mechanisms. The findings suggest that naringenin could be a promising candidate for addressing dual challenges of inflammation and impaired osteogenesis in conditions like osteoporosis and rheumatoid arthritis.